Alpha Mannosidosis Market Report 2025

The alpha mannosidosis market size has grown rapidly in recent years. It will grow from $15.1 billion in 2024 to $18.02 billion in 2025 at a compound annual growth rate (CAGR) of 19.3%. The growth in the historic period can be attributed to emerging market growth, urbanization, increased demand for man-made fibers, and government initiatives for the textile industry.

The alpha mannosidosis market size is expected to see rapid growth in the next few years. It will grow to $34.52 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to global population growth and urbanization, increasing e-commerce, increasing demand for sportswear, increasing penetration of organized retail in developing economies, and increasing penetration of social media. Major trends in the forecast period include increasing the use of enzyme therapy, adopting the use of hematopoietic stem cell transplantation, and adopting the use of cisterna magna infusion.

The increasing demand for precision medicine is anticipated to drive the growth of the alpha mannosidosis market. Precision medicine is a personalized healthcare approach that considers individual differences in patients' genes, environments, and lifestyles to optimize treatment and prevention strategies. The growth of precision medicine is fueled by advancements in genomic technologies and data analytics, which facilitate more accurate identification of genetic variations and their effects on health. Furthermore, the rising demand for personalized treatment options, coupled with growing awareness of the limitations of one-size-fits-all approaches, has heightened interest in tailored healthcare solutions. Precision medicine promotes the development of targeted therapies specifically designed for the genetic mutations and patient profiles associated with this rare disorder. For example, in February 2024, data from the Personalized Medicine Coalition (PMC), a U.S.-based nonprofit umbrella organization, revealed that the FDA approved 16 new personalized treatments for rare diseases in 2023, a significant increase from just six approvals in 2022. Consequently, the rising demand for precision medicine is propelling the growth of the alpha mannosidosis market.

The growth of the alpha mannosidosis market is significantly influenced by the increasing healthcare expenditure. Healthcare expenditure encompasses costs related to family planning services, nutrition programs, emergency medical assistance, and health services. Government initiatives, grants, and incentives play a crucial role in providing financial support and encouraging research and development in the field of rare diseases, including alpha mannosidosis. For instance, data released by the Centers for Medicare & Medicaid Services (CMS) in June 2023 indicates that the national health expenditure (NHE) in the United States reached $4.3 trillion in 2021, accounting for 18.3% of the Gross Domestic Product (GDP). This growing healthcare expenditure reflects a commitment to supporting healthcare initiatives, contributing to the advancement of treatments for rare diseases. Consequently, the increasing healthcare expenditure is expected to drive the alpha mannosidosis market.

Major companies in the alpha mannosidosis market are actively focused on developing enzyme replacement therapies to address rare alpha-mannosidosis. Enzyme replacement therapy involves supplying exogenous alpha-mannosidase, which helps reduce the accumulation of mannose-rich oligosaccharides in various tissues and organs, a characteristic feature of alpha-mannosidosis contributing to its pathological effects. A notable example is Chiesi Global Rare Diseases, a U.S.-based pharmaceutical company, which, in February 2023, launched Lamzede (velmanase alfa), the first enzyme replacement therapy authorized in the United States for treating alpha-mannosidosis. Lamzede acts similarly to the human body's alpha-mannosidase enzyme, restoring normal cellular activity in patients. The treatment involves a weekly injection of 10 mg of Lamzede.

The rise in biopharmaceutical research and development (R&D) investments is playing a significant role in driving the growth of the alpha mannosidosis market. Research and development involve the time and resources a company allocates to creating new products and improving existing ones. Enhanced understanding of the molecular underpinnings of alpha mannosidosis, along with advancements in genetic therapies, has facilitated the development of potential treatments. R&D initiatives from pharmaceutical companies and academic institutions are pivotal in fostering innovation in this area. For instance, in September 2022, the UK government reported that spending on pharmaceutical research and development reached $18.9 billion (£15.3 billion) in 2020, with a budget allocation of $49.2 billion (£39.8 billion) for R&D from 2022 to 2025. Additionally, in March 2023, Merck, a Germany-based biopharmaceutical manufacturer, announced a 3.9% increase in its R&D spending for 2022 compared to 2021. Similarly, in January 2023, Roche Holding AG, a Switzerland-based biopharmaceutical manufacturer, reported a 3.7% rise in its R&D expenditure for 2022 compared to the previous year. Consequently, the increased investments in research and development by biopharmaceutical companies are fueling the growth of the alpha mannosidosis market.

In April 2023, Italian pharmaceutical company Chiesi Farmaceutici acquired Amryt Pharma, a UK-based pharmaceutical company, for $1.25 billion. This strategic acquisition enhances Chiesi's Global Rare Diseases business division by incorporating Amryt Pharma's approved commercial products for rare diseases into its existing portfolio. Amryt Pharma is recognized for its dedication to developing and delivering innovative treatments for rare diseases.

Major companies operating in the alpha mannosidosis market include Chiesi Farmaceutici S.p.A., Cipla, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Merck, Bristol-Myers Squibb, Novartis AG, Amgen, Centogene, Zymenex A/S, Albumedix Ltd, Kite Pharma, Catalent, Freeline Therapeutics, Avectas, DiNAQOR AG, Vivet Therapeutics, Allergan, PsiOxus Therapeutics, Herantis Pharma Plc, Biocad, Celgene Corporation, Johnson & Johnson, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Bayer AG, PTC Therapeutics, Gilead Sciences Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Pfizer S.R.L., AstraZeneca plc, Biogen SA, Sanofi, Adcock Ingram.

North America was the largest region in the alpha mannosidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alpha mannosidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the alpha mannosidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Alpha mannosidosis is a rare genetic disorder characterized by the body's inability to effectively break down specific groups of complex sugars, leading to the accumulation of these sugars in various organs and systems, including the central nervous system. The impact of sugar buildup can vary significantly from person to person.

The primary therapeutic approaches for alpha mannosidosis include bone marrow transplant (BMT) and enzyme replacement therapy (ERT). A bone marrow transplant involves replacing dysfunctional marrow with healthy marrow to address the underlying genetic defect. Enzyme replacement therapy aims to supplement or replace a deficient enzyme in individuals lacking the enzyme or having a deficiency. The indications for alpha mannosidosis are classified into Type I, Type II, and Type III, and these therapeutic interventions are implemented across various healthcare settings, including hospitals and specialty clinics. These treatments play a crucial role in managing the symptoms and addressing the underlying genetic abnormalities associated with alpha mannosidosis.

The alpha mannosidosis market research report is one of a series of new reports that provides alpha mannosidosis market statistics, including alpha mannosidosis industry global market size, regional shares, competitors with an alpha mannosidosis market share, detailed alpha mannosidosis market segments, market trends and opportunities, and any further data you may need to thrive in the alpha mannosidosis industry. This alpha mannosidosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The alpha mannosidosis market includes revenues earned by entities by intellectual disability, skeletal abnormalities, hearing loss, and muscle weakness. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.